Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives

Australian and New Zealand Journal of Psychiatry

Volumn 53, Issue 7, 2019, Pages 651-662

  Coello, Klara ^a,c   Kjærstad, Hanne L ^a,c   Stanislaus, Sharleny ^a,c   Melbye, Sigurd ^a,c   Faurholt Jepsen, Maria ^a,c   Miskowiak, Kamilla Woznica ^a,c   McIntyre, Roger S ^b   Vinberg, Maj ^a,c   Kessing, Lars V ^a,c   Munkholm, Klaus ^a,c  

^a Psychiatric Center Copenhagen   (Denmark)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bipolar disorder; cardiovascular risk; Framingham risk score; newly diagnosed; unaffected relatives

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; AGE; ANTHROPOMETRY; ARTICLE; BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE DURATION; DSM-5; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; FIRST-DEGREE RELATIVE; FRAMINGHAM RISK SCORE; GENDER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HOSPITALIZATION; HUMAN; HYPERTENSION; ICD-10; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; LIFE EXPECTANCY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOOD DISORDER; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RISK ASSESSMENT; SMOKING; SUICIDE ATTEMPT; SYSTOLIC BLOOD PRESSURE; YOUNG ADULT; AGED; CASE CONTROL STUDY; FAMILY; INCIDENCE; MIDDLE AGED; RISK;

ADULT; AGED; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FAMILY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK; YOUNG ADULT;

EID: 85060149205     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867418815987     Document Type: Article

References (47)

1. Abosi O, Lopes S, Schmitz S. (2018) Cardiometabolic effects of psychotropic medications. Hormone Molecular Biology and Clinical Investigation. Epub ahead of print 10 January. DOI: 10.1515/hmbci-2017-0065.
2. Afshin A, Forouzanfar MH, Reitsma MB. (2017) Health effects of overweight and obesity in 195 countries over 25 years. New England Journal of Medicine 377: 13–27.
3. Alberti G, Zimmet P, Shaw J. (2006) The IDF consensus worldwide definition of the metabolic syndrome. The Lancet 366: 1059–1062.
4. Albertini RA, Ferrer DG, Romagnoli PA. (2017) Association between cardiovascular disease risk scores and subclinical atherosclerosis prevalence in non-elderly adult patients from Argentina. International Journal of Cardiovascular Imaging 33: 1521–1529.
5. Alonso J, Petukhova M, Vilagut G. (2011) Days out of role due to common physical and mental conditions: Results from the WHO World Mental Health surveys. Molecular Psychiatry 16: 1234–1246.
6. Amare AT, Schubert KO, Klingler-Hoffmann M. (2017) The genetic overlap between mood disorders and cardiometabolic diseases: A systematic review of genome wide and candidate gene studies. Translational Psychiatry 7: e1007.
7. Baldessarini RJ, Tondo L, Baethge CJ. (2007) Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disorders 9: 386–393.
8. Berry JD, Liu K, Folsom AR. (2009) Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: The coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 119: 382–389.
9. Calkin CV, Ruzickova M, Uher R. (2015) Insulin resistance and outcome in bipolar disorder. British Journal of Psychiatry 206: 52–57.
10. Clemente AS, Diniz BS, Nicolato R. (2015) Bipolar disorder prevalence: A systematic review and meta-analysis of the literature. Revista Brasileira de Psiquiatria 37: 155–161.
11. Cornier MA, Despres JP, Davis N. (2011) Assessing adiposity: A scientific statement from the American Heart Association. Circulation 124: 1996–2019.
12. Correll CU, Frederickson AM, Kane JM. (2008) Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 10: 788–797.
13. Correll CU, Solmi M, Veronese N. (2017) Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16: 163–180.
14. Craig CL, Marshall AL, Sjostrom M. (2003) International Physical Activity Questionnaire: 12-country reliability and validity. Medicine and Science in Sports and Exercise 35: 1381–1395.
15. Evans-Lacko SE, Zeber JE, Gonzalez JM. (2009) Medical comorbidity among youth diagnosed with bipolar disorder in the United States. Journal of Clinical Psychiatry 70: 1461–1466.
16. Fiedorowicz JG, Jancic D, Potash JB. (2014) Vascular mortality in participants of a bipolar genomics study. Psychosomatics 55: 485–490.
17. Fiedorowicz JG, Solomon DA, Endicott J. (2009) Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosomatic Medicine 71: 598–606.
18. Goldstein BI, (2017) Bipolar disorder and the vascular system: Mechanisms and new prevention opportunities. Canadian Journal of Cardiology 33: 1565–1576.
19. Goldstein BI, Carnethon MR, Matthews KA. (2015a) Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: A scientific statement from the American Heart Association. Circulation 132: 965–986.
20. Goldstein BI, Fagiolini A, Houck P. (2009) Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disorders 11: 657–662.
21. Goldstein BI, Schaffer A, Wang S. (2015b) Excessive and premature new-onset cardiovascular disease among adults with bipolar disorder in the US NESARC cohort. Journal of Clinical Psychiatry 76: 163–169.
22. Guha P, Bhowmick K, Mazumder P. (2014) Assessment of insulin resistance and metabolic syndrome in drug naive patients of bipolar disorder. Indian Journal of Clinical Biochemistry 29: 51–56.
23. Hamilton M, (1960) A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23: 56–62.
24. Kemp DE, Gao K, Chan PK. (2010) Medical comorbidity in bipolar disorder: Relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disorders 12: 404–413.
25. Kessing LV, Vradi E, Andersen PK, (2015a) Life expectancy in bipolar disorder. Bipolar Disorders 17: 543–548.
26. Kessing LV, Vradi E, McIntyre RS. (2015b) Causes of decreased life expectancy over the life span in bipolar disorder. Journal of Affective Disorders 180: 142–147.
27. Kessing LV, Munkholm K, Faurholt-Jepsen M. (2017) The bipolar illness onset study: Research protocol for the BIO cohort study. BMJ Open 7: e015462.
28. Kessler RC, Angermeyer M, Anthony JC. (2007) Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry 6: 168–176.
29. Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H. (2013) Antipsychotics and mortality in first-onset schizophrenia: Prospective Finnish register study with 5-year follow-up. Schizophrenia Research 150: 274–280.
30. Laing ST, Smulevitz B, Vatcheva KP. (2012) High prevalence of subclinical atherosclerosis by carotid ultrasound among Mexican Americans: Discordance with 10-year risk assessment using the Framingham risk score. Echocardiography 29: 1224–1232.
31. Laursen TM, Wahlbeck K, Hallgren J. (2013) Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS ONE 8: e67133.
32. Loria CM, Liu K, Lewis CE. (2007) Early adult risk factor levels and subsequent coronary artery calcification: The CARDIA study. Journal of the American College of Cardiology 49: 2013–2020.
33. McPherson R, Tybjaerg-Hansen A, (2016) Genetics of coronary artery disease. Circulation Research 118: 564–578.
34. Naiberg MR, Newton DF, Collins JE. (2016) Elevated triglycerides are associated with decreased executive function among adolescents with bipolar disorder. Acta Psychiatrica Scandinavica 134: 241–248.
35. Osborn DP, Hardoon S, Omar RZ. (2015) Cardiovascular risk prediction models for people with severe mental illness: Results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry 72: 143–151.
36. Osby U, Brandt L, Correia N. (2001) Excess mortality in bipolar and unipolar disorder in Sweden. Archives of General Psychiatry 58: 844–850.
37. Pencina MJ, D’Agostino RB, Sr Larson MG. (2009a) Available at: https://www.framinghamheartstudy.org/fhs-risk-functions/cardiovascular-disease-30-year-risk/ (accessed January 15, 2018).
38. Pencina MJ, D’Agostino RB, Sr Larson MG. (2009b) Predicting the 30-year risk of cardiovascular disease: The Framingham heart study. Circulation 119: 3078–3084.
39. Sobczak S, Honig A, Christophe A. (2004) Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychological Medicine 34: 103–112.
40. SST (2017) Available at: www.sst.dk/da/udgivelser/2018/danskernes-rygevaner-2017 (accessed March 20, 2018).
41. Taylor V, McKinnon MC, Macdonald K. (2010) Adults with mood disorders have an increased risk profile for cardiovascular disease within the first 2 years of treatment. Canadian Journal of Psychiatry 55: 362–368.
42. Tiihonen J, Mittendorfer-Rutz E, Torniainen M. (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. American Journal of Psychiatry 173: 600–606.
43. Weiner M, Warren L, Fiedorowicz JG, (2011) Cardiovascular morbidity and mortality in bipolar disorder. Annals of Clinical Psychiatry 23: 40–47.
44. Westman J, Hallgren J, Wahlbeck K. (2013) Cardiovascular mortality in bipolar disorder: A population-based cohort study in Sweden. BMJ Open 3: e002373.
45. Wimberley T, MacCabe JH, Laursen TM. (2017) Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. American Journal of Psychiatry 174: 990–998.
46. Wing JK, Babor T, Brugha T. (1990) SCAN. Schedules for clinical assessment in neuropsychiatry. Archives of General Psychiatry 47: 589–593.
47. Young RC, Biggs JT, Ziegler VE. (1978) A rating scale for mania: Reliability, validity and sensitivity. British Journal of Psychiatry 133: 429–435.